JCR Pharmaceuticals , Ltd. EBIT

The latest EBIT for JCRRF is $1.8B as of June 2026. That compares with $-7.7B in the prior-year period — up 123.9% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside JCR Pharmaceuticals , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, JCRRF's EBIT moved from $-7.7B to $1.8B — a 123.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in JCR Pharmaceuticals , Ltd.'s operating scale or balance-sheet position.

Against its sector companies, JCRRF currently prints $1.8B for EBIT, while the sector average sits near $2.6T. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at JCR Pharmaceuticals , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $1.8B for JCRRF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting JCRRF's EBIT ($1.8B), review year-over-year change from $-7.7B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.